193 related articles for article (PubMed ID: 33277507)
21. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
22. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
Hoogendoorn M; Corro Ramos I; Baldwin M; Luciani L; Fabron C; Detournay B; Rutten-van Mölken MPMH
Int J Chron Obstruct Pulmon Dis; 2019; 14():447-456. PubMed ID: 30863045
[TBL] [Abstract][Full Text] [Related]
23. Study Design of VESUTO
Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
[TBL] [Abstract][Full Text] [Related]
24. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
[TBL] [Abstract][Full Text] [Related]
25. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
26. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
27. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
[TBL] [Abstract][Full Text] [Related]
28. Tiotropium/Olodaterol: A Review in COPD.
Dhillon S
Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
[TBL] [Abstract][Full Text] [Related]
29. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness
Maltais F; Aumann JL; Kirsten AM; Nadreau É; Macesic H; Jin X; Hamilton A; O'Donnell DE
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30655277
[TBL] [Abstract][Full Text] [Related]
30. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
31. Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
Troosters T; Maltais F; Leidy N; Lavoie KL; Sedeno M; Janssens W; Garcia-Aymerich J; Erzen D; De Sousa D; Korducki L; Hamilton A; Bourbeau J
Am J Respir Crit Care Med; 2018 Oct; 198(8):1021-1032. PubMed ID: 29664681
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Kato M; Takizawa A; Sakamoto W; Grönke L; Tetzlaff K; Fukuchi Y
Respir Investig; 2017 Mar; 55(2):121-129. PubMed ID: 28274527
[TBL] [Abstract][Full Text] [Related]
33. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
Cataldo D
Rev Med Liege; 2016 Jun; 71(6):308-313. PubMed ID: 28383865
[TBL] [Abstract][Full Text] [Related]
34. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
Wang Z; Tadayasu Y; Hu N; Shu S; Hu C; Luo Z
Pulm Pharmacol Ther; 2020 Aug; 63():101944. PubMed ID: 32916296
[TBL] [Abstract][Full Text] [Related]
36. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
[TBL] [Abstract][Full Text] [Related]
37. Effects of lung deflation induced by tiotropium/olodaterol on the cardiocirculatory responses to exertion in COPD.
Berton DC; Marques RD; Palmer B; O'Donnell DE; Neder JA
Respir Med; 2019 Oct; 157():59-68. PubMed ID: 31522031
[TBL] [Abstract][Full Text] [Related]
38. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
Takahashi K; Uchida M; Kato G; Takamori A; Kinoshita T; Yoshida M; Tajiri R; Kojima K; Inoue H; Kobayashi H; Sadamatsu H; Tashiro H; Tanaka M; Hayashi S; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
Int J Chron Obstruct Pulmon Dis; 2020; 15():2115-2126. PubMed ID: 32982204
[TBL] [Abstract][Full Text] [Related]
39. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
40. Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination.
Rogliani P; Ritondo BL; Zerillo B; Cazzola M; Matera MG; Calzetta L
COPD; 2020 Apr; 17(2):215-223. PubMed ID: 32252547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
